Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Diseases | 3 | 2019 | 125 | 0.600 |
Why?
|
Kidney Neoplasms | 3 | 2015 | 69 | 0.560 |
Why?
|
Podocytes | 4 | 2023 | 91 | 0.520 |
Why?
|
Carcinoma, Renal Cell | 2 | 2015 | 43 | 0.470 |
Why?
|
Biopsy, Fine-Needle | 7 | 2013 | 61 | 0.450 |
Why?
|
Glomerulonephritis, IGA | 1 | 2011 | 8 | 0.390 |
Why?
|
Carcinoma, Papillary | 1 | 2010 | 21 | 0.360 |
Why?
|
Lymphatic Metastasis | 3 | 2010 | 104 | 0.360 |
Why?
|
Tumor Virus Infections | 1 | 2009 | 17 | 0.340 |
Why?
|
Polyomavirus Infections | 1 | 2009 | 24 | 0.340 |
Why?
|
Adenoma | 2 | 2021 | 46 | 0.290 |
Why?
|
Carcinosarcoma | 1 | 2006 | 4 | 0.280 |
Why?
|
Uterine Neoplasms | 1 | 2006 | 13 | 0.280 |
Why?
|
Pleural Neoplasms | 1 | 2006 | 10 | 0.260 |
Why?
|
Mesothelioma | 1 | 2006 | 11 | 0.260 |
Why?
|
Enterocolitis | 1 | 2005 | 5 | 0.260 |
Why?
|
Candidiasis | 1 | 2005 | 19 | 0.260 |
Why?
|
Carcinoma, Lobular | 1 | 2005 | 17 | 0.260 |
Why?
|
Liver Neoplasms | 2 | 2011 | 121 | 0.260 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2005 | 29 | 0.260 |
Why?
|
Immunocompromised Host | 1 | 2005 | 50 | 0.250 |
Why?
|
Colonoscopy | 2 | 2021 | 53 | 0.250 |
Why?
|
Cerebral Hemorrhage | 1 | 2005 | 140 | 0.230 |
Why?
|
Humans | 23 | 2023 | 30997 | 0.220 |
Why?
|
Breast Neoplasms | 2 | 2015 | 376 | 0.220 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 2 | 2023 | 44 | 0.220 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2015 | 39 | 0.210 |
Why?
|
Proteinuria | 2 | 2023 | 83 | 0.210 |
Why?
|
Coloring Agents | 1 | 2021 | 13 | 0.190 |
Why?
|
Antibodies | 1 | 2021 | 67 | 0.190 |
Why?
|
Mice | 6 | 2023 | 1683 | 0.180 |
Why?
|
Female | 12 | 2019 | 16983 | 0.170 |
Why?
|
Paraproteinemias | 1 | 2019 | 6 | 0.160 |
Why?
|
Inducible T-Cell Co-Stimulator Ligand | 1 | 2019 | 7 | 0.160 |
Why?
|
Integrin alphaVbeta3 | 1 | 2019 | 23 | 0.160 |
Why?
|
Middle Aged | 9 | 2015 | 10195 | 0.150 |
Why?
|
CD11b Antigen | 1 | 2017 | 18 | 0.140 |
Why?
|
Toll-Like Receptors | 1 | 2017 | 29 | 0.140 |
Why?
|
Receptor, ErbB-4 | 1 | 2016 | 3 | 0.140 |
Why?
|
Adult | 5 | 2015 | 8931 | 0.140 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 8 | 0.140 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 161 | 0.140 |
Why?
|
Diabetic Nephropathies | 1 | 2016 | 29 | 0.140 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2016 | 32 | 0.140 |
Why?
|
MicroRNAs | 1 | 2016 | 47 | 0.140 |
Why?
|
Animals | 6 | 2023 | 4723 | 0.130 |
Why?
|
Receptor, ErbB-2 | 2 | 2006 | 49 | 0.130 |
Why?
|
Macrophages | 1 | 2017 | 137 | 0.130 |
Why?
|
Up-Regulation | 1 | 2016 | 177 | 0.130 |
Why?
|
Granulomatous Mastitis | 1 | 2015 | 3 | 0.130 |
Why?
|
Angiomyolipoma | 1 | 2015 | 3 | 0.120 |
Why?
|
Biopsy | 3 | 2021 | 249 | 0.120 |
Why?
|
Retrospective Studies | 5 | 2019 | 3658 | 0.110 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2017 | 221 | 0.110 |
Why?
|
Wilms Tumor | 1 | 2013 | 10 | 0.110 |
Why?
|
Lung Neoplasms | 3 | 2011 | 691 | 0.110 |
Why?
|
Male | 7 | 2017 | 16445 | 0.110 |
Why?
|
Urologic Neoplasms | 1 | 2011 | 4 | 0.090 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2011 | 14 | 0.090 |
Why?
|
Rhabdomyosarcoma | 1 | 2010 | 7 | 0.090 |
Why?
|
Bone Neoplasms | 2 | 2011 | 120 | 0.090 |
Why?
|
Trisomy | 1 | 2010 | 3 | 0.090 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2010 | 9 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2010 | 24 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 35 | 0.090 |
Why?
|
Cytodiagnosis | 2 | 2010 | 18 | 0.090 |
Why?
|
Nephrectomy | 1 | 2010 | 32 | 0.090 |
Why?
|
Disease-Free Survival | 1 | 2010 | 208 | 0.090 |
Why?
|
BK Virus | 1 | 2009 | 11 | 0.090 |
Why?
|
Soft Tissue Neoplasms | 1 | 2010 | 59 | 0.080 |
Why?
|
Adenocarcinoma | 1 | 2011 | 206 | 0.080 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2011 | 192 | 0.080 |
Why?
|
Fatal Outcome | 2 | 2006 | 64 | 0.080 |
Why?
|
Chondroma | 1 | 2008 | 5 | 0.080 |
Why?
|
Biomarkers, Tumor | 1 | 2010 | 217 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2009 | 126 | 0.080 |
Why?
|
Tissue Array Analysis | 1 | 2006 | 7 | 0.070 |
Why?
|
Mice, Knockout | 2 | 2019 | 323 | 0.070 |
Why?
|
Reed-Sternberg Cells | 1 | 2006 | 2 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2006 | 16 | 0.070 |
Why?
|
Bronchi | 1 | 2006 | 13 | 0.070 |
Why?
|
Chondrocytes | 1 | 2008 | 208 | 0.070 |
Why?
|
Cyclooxygenase 2 | 1 | 2006 | 35 | 0.070 |
Why?
|
Carcinoma, Large Cell | 1 | 2006 | 17 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2006 | 20 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2006 | 81 | 0.070 |
Why?
|
ErbB Receptors | 1 | 2006 | 81 | 0.070 |
Why?
|
Arteriovenous Malformations | 1 | 2006 | 4 | 0.070 |
Why?
|
Gastric Mucosa | 1 | 2006 | 14 | 0.070 |
Why?
|
Stomach | 1 | 2006 | 19 | 0.070 |
Why?
|
Arteries | 1 | 2006 | 20 | 0.070 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2006 | 26 | 0.070 |
Why?
|
Receptors, Progesterone | 1 | 2005 | 33 | 0.070 |
Why?
|
Cadherins | 1 | 2005 | 37 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2006 | 430 | 0.060 |
Why?
|
Neoplasm Staging | 1 | 2006 | 404 | 0.060 |
Why?
|
Receptors, Estrogen | 1 | 2005 | 70 | 0.060 |
Why?
|
Signal Transduction | 2 | 2019 | 498 | 0.060 |
Why?
|
Integrins | 1 | 2023 | 21 | 0.060 |
Why?
|
Aged | 4 | 2015 | 10048 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2015 | 5189 | 0.050 |
Why?
|
Staining and Labeling | 1 | 2021 | 22 | 0.050 |
Why?
|
Fluorescent Antibody Technique | 1 | 2021 | 78 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 1 | 2005 | 817 | 0.050 |
Why?
|
Treatment Outcome | 1 | 2010 | 3806 | 0.050 |
Why?
|
Observer Variation | 1 | 2021 | 118 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 407 | 0.050 |
Why?
|
Receptor, PAR-2 | 1 | 2019 | 4 | 0.040 |
Why?
|
Protein Domains | 1 | 2019 | 11 | 0.040 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 3 | 0.040 |
Why?
|
Adipocytes | 1 | 2019 | 14 | 0.040 |
Why?
|
Amino Acid Motifs | 1 | 2019 | 18 | 0.040 |
Why?
|
Protein Multimerization | 1 | 2019 | 19 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2019 | 24 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2019 | 55 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 2019 | 75 | 0.040 |
Why?
|
Immunoglobulin A | 1 | 2019 | 20 | 0.040 |
Why?
|
HEK293 Cells | 1 | 2019 | 70 | 0.040 |
Why?
|
Symptom Assessment | 1 | 2019 | 23 | 0.040 |
Why?
|
Glomerular Filtration Rate | 1 | 2019 | 61 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 270 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2019 | 261 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2021 | 818 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 386 | 0.040 |
Why?
|
Disease Management | 1 | 2019 | 126 | 0.040 |
Why?
|
Mice, Inbred MRL lpr | 1 | 2017 | 3 | 0.040 |
Why?
|
Interferon Regulatory Factor-3 | 1 | 2017 | 3 | 0.040 |
Why?
|
Interferon Regulatory Factor-7 | 1 | 2017 | 4 | 0.040 |
Why?
|
Forkhead Box Protein O3 | 1 | 2017 | 7 | 0.040 |
Why?
|
Interferon Type I | 1 | 2017 | 22 | 0.040 |
Why?
|
Ribonucleases | 1 | 2016 | 9 | 0.040 |
Why?
|
Erlotinib Hydrochloride | 1 | 2016 | 19 | 0.030 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2016 | 32 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2016 | 24 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 54 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 318 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2019 | 782 | 0.030 |
Why?
|
Ultrasonography, Mammary | 1 | 2015 | 10 | 0.030 |
Why?
|
Biomarkers | 1 | 2019 | 733 | 0.030 |
Why?
|
Tuberous Sclerosis | 1 | 2015 | 15 | 0.030 |
Why?
|
Mammography | 1 | 2015 | 43 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2019 | 1133 | 0.030 |
Why?
|
Incidence | 1 | 2015 | 785 | 0.030 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2011 | 13 | 0.020 |
Why?
|
Radiography | 1 | 2013 | 695 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 2588 | 0.020 |
Why?
|
Chondroblastoma | 1 | 2008 | 2 | 0.020 |
Why?
|
Histocytological Preparation Techniques | 1 | 2008 | 3 | 0.020 |
Why?
|
Fibroma | 1 | 2008 | 4 | 0.020 |
Why?
|
Chondrosarcoma | 1 | 2008 | 37 | 0.020 |
Why?
|
Adolescent | 1 | 2006 | 2401 | 0.010 |
Why?
|